Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

OPNT / Opiant Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-12 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  February 12, 2018   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)               Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

2018-02-12 reuters
* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003 (3-0)

OPNT / Opiant Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  February 8, 2018   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)               Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.

BRIEF-Opiant Pharmaceuticals To Record About $11.7 Million In Royalty

2018-02-08 reuters
* OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE (3-0)

OPNT / Opiant Pharmaceuticals, Inc. 8-K (Current Report)

2018-01-16 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  January 11, 2018   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)               Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.

OPNT / Opiant Pharmaceuticals, Inc. 8-K (Current Report)

2018-01-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  January 2, 2018   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)               Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.

OPNT / Opiant Pharmaceuticals, Inc. ER

2018-01-01 sec.gov
Mail Stop 3561 October 25, 2017 Via E-mail Dr. Roger Crystal Chief Executive Officer Opiant Pharmaceuticals, Inc. 201 Santa Monica Blvd., Suite 500 Santa Monica, CA 90401 Re: Opiant Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed October 13, 2017 File No. 333-220976 Dear Dr. Crystal: This is to advise you that we have not reviewed and will not review your registration statement.

OPNT / Opiant Pharmaceuticals, Inc. ESP

2018-01-01 sec.gov
Document OPIANT PHARMACEUTICALS, INC. 201 Santa Monica Boulevard, Suite 500 Santa Monica, California 90401 November 3, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4561 Attn:    John Reynolds Re:    Opiant Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-220976     Filed October 13, 2017 Dear Mr.

OPNT / Opiant Pharmaceuticals, Inc. 8-K (Current Report)

2017-12-27 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  December 20, 2017   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)               Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.

BRIEF-Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose

2017-12-20 reuters
* OPIANT PHARMACEUTICALS -EXPECTS ,BEGINNING Q1 2018, CO WILL RECEIVE 90% ROYALTY, MILESTONE PAYMENTS RELATED TO NARCAN SALES DIRECTLY FROM ADAPT PHARMA​ (3-1)

OPNT / Opiant Pharmaceuticals, Inc. OPIANT 12.13.17 8K (Current Report)

2017-12-13 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  December 8, 2017   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)             Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.

OPNT / Opiant Pharmaceuticals, Inc. OPIANT 12/8/17 8-K (Current Report)

2017-12-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  December 8, 2017   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)               Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.

Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result

2017-12-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day earlier. (402-3)

OPNT / Opiant Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2017-12-04 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended October 31, 2017  or  ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from ______to______.   Commission File Number: 001-38193   OPIANT PHARMACEUTICALS, INC.

OPNT / Opiant Pharmaceuticals, Inc. 8-K (Current Report)

2017-12-01 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  November 30, 2017   OPIANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)               Delaware   001-38193   46-4744124 (State or other jurisdiction of  incorporation)    (Commission File Number   (IRS Employer Identification No.


CUSIP: 683750103